New Era !!! New Growth !!! New Beginnings !!!

View all discussions

View all discussions

New Era !!! New Growth !!! New Beginnings !!!

Raymond C. Dabney Discussion started by Raymond C. Dabney 5 years ago

Just Released !!! New Era !!! New Growth !!! New Beginnings !!!

Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Company Goes Private as It Enters Into Step (2) of Its Growth Transition, Enabling Full Transparency and Revenue Growth

Irvine, CA - (NewMediaWire) - October 21, 2019 - Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has agreed to go private under sanctions by the U.S. Securities and Exchange Commission (“SEC”). All Cannabis Science shareholders and their shareholdings will remain intact under the same name and entity, Cannabis Science Inc., a Nevada Corporation. Cannabis Science shares will no longer be quoted or traded on any stock market exchange.

Once the private corporation status takes effect the Company’s President will begin the steps to file a Dutch auction IPO targeting $25,000,000 USD or more with all current shareholders intact with completed financials, first rights IPO offerings for current shareholders, new shareholder IPO offerings, and a new company trading symbol. All Cannabis Science shareholders of record as of the last day trading whether individuals or entities will be eligible for the first rights IPO offering and shareholder loyalty gifts; all other new shareholders will be officially closed-out once the transition to private company status has occurred.

Cannabis Science Inc. President and CEO Raymond C. Dabney stated, “This is probably one of the most exciting times for Cannabis Science in terms of the rate of our growth and the number of international positive cash flow projects the company is entering into right now through its Economic Development Program (CBIS-EDP). We are certainly transitioning into a very large multi-national conglomerate real fast and we must guide this massive battleship home with ease and control. As we transition into ‘Step (2)’ of this growth, the associated growing pains we are experiencing right now have certainly shaken up and taken a toll on the company’s operations and our complete line of auditing and fully reporting capabilities. After extensive communications with the SEC regarding our business growth and how best to manage it with the SEC’s reporting requirements and information-flow constraints, I have come to realize that this is the best course of action right now so we can focus on growing our business and becoming cash-flow positive. With that in mind, I agree with the SEC on this one; it is time to make the required moves to protect our successful business growth and as a result protect our shareholders’ value.

“All shareholders will be able to register on www.iCannabinoid.com to get live access to current financial information, share trading status, new acquisitions, partnerships and opportunities, news releases, progress reports, presentations, new financings, first rights IPO opportunities and shareholder loyalty gifts. As well, inside of the iCannabinoid website we will be offering businesses, students, and entrepreneurs everywhere full access to our university economic development plan (CBIS-EDP) categorized by Countries, Regions, Industries, Educational, Leadership, and Partnership Opportunities. We will be accepting pre-registrations for our hybrid-University courses and accepting bid tenders for partnerships, operations and expansions in the many different industries we are targeting for the CBIS-EDP.

“Our strong partnership opportunities is the main reason our CBIS-EDP is seeing such success; for the past ten years we have built up a robust pipeline of economic growth opportunities worldwide centered around education, job creation, drug development, agriculture, high-tech, banking & finance, communications, real estate & construction, medical services, security, TV & media, mining & natural resources, political & government relations, manufacturing, teaching, sales & marketing, retail services, warehousing & distribution, and entrepreneurial business incubators for those who wish to own their own businesses and create jobs anywhere, even in your own community, in virtually any industry worldwide.

“These new initiatives have created significant reporting requirements for the Company in multiple jurisdictions worldwide, while Cannabis Science is simultaneously investing in the necessary infrastructure to successfully execute these exciting initiatives. By going private, the Company will have the opportunity to stabilize its growth and put the necessary systems in place to ensure that Cannabis Science successfully maintains its growth over the long-term, and over the short-term the Company will be able to move at the speed of light. Cannabis Science’s CEO will be empowered to move much faster to structure new partnerships and acquisitions to add value and liquidity to the Company’s shares through partnerships and acquisitions with new private and public companies operating on exchanges worldwide, to take advantage of and better align with Cannabis Science global operations.

“Over the last several years, Cannabis Science has invested heavily in its drug development, education, and economic development initiatives. As for drug development, Cannabis Science has a tremendous pipeline of potential critical ailment products and is planning for clinical trials early next year. Cannabis Science also has a number of products currently available and under development for the state and over-the-counter (OTC) markets. Similarly, Cannabis Science has made considerable progress with its education and economic development programs internationally.

"This is what it’s all about; the CBIS-EDP is real, down to earth, accessible economic development plans, industry specific enhancements, job creation, education, food and drug distribution. We have made this program available to everyone in virtually any demographic worldwide that needs economic industry stimulation or cost-effective drug development for medical issues, restructure for economic growth, education, and jobs for the people. We just made the World Series, and its game on! Looking forward to seeing you all live on iCannabinoid!” Concludes Mr. Dabney.

About Cannabis Science, Inc.

Cannabis Science is the first publicly-traded cannabinoid company on the market, and is a leader in the research and development of cannabinoid-based medicines and associated delivery technologies. Cannabis Science and its research collaborators are currently conducting pre-clinical research on cannabinoid-based medicines with plans to transition to clinical trials on a number of products this year. Targeted indications include Lung Cancer, Pancreatic Cancer, Chronic Prostatitis, Obsessive Compulsive Disorder (OCD), Oro-bucco-lingual Dyskinesias, Oxidative Stress, Psychosis, and Post Traumatic Stress Disorder (PTSD). CBIS is also currently in negotiations to license the Company’s U.S. patent number 9,763,991 for the Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, including Sleep Disorders. CBIS recently announced its drug-development pipeline (www.cannabisscience.com) and the transition into clinical trials as well as other major company initiatives.

Cannabis Science takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, neurological conditions, and other indications as identified previously. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

Contact Information

Cannabis Science, Inc.

Mr. Raymond C. Dabney

President & CEO, Co-Founder

raymond.dabney@cannabisscience.com

Tel: 1-310-650-3788

www.iCannabinoid.com

Connect, Learn, and Share!

For Live Chat and Live Updates

Replies

Dino Baschiera How, when and where will we know when they are going to do that....I have yet to receive any letter in the mail stating their time line...Donna I... Show more 4 years ago

Kelly D Jackson Not sure what to think about this. Not happy ... but I’ll guess we will see what happens. 4 years ago

Richard A Nenzel Perhaps an update is in order??? A lot of nervous investors. 4 years ago

Bill Boone My question is regarding the following, which was taken from Mr. Dabneys' entry, above: "Once the private corporation status takes effect the... Show more 4 years ago

My question is regarding the following, which was taken from Mr. Dabneys' entry, above:  "Once the private corporation status takes effect the Company’s President will begin the steps to file a Dutch auction IPO targeting $25,000,000 USD or more with all current shareholders intact with completed financials, first rights IPO offerings for current shareholders, new shareholder IPO offerings, and a new company trading symbol. All Cannabis Science shareholders of record as of the last day trading whether individuals or entities will be eligible for the first rights IPO offering and shareholder loyalty gifts; "  In this particular statement, there is a reference to "All Cannabis Science shareholders of record".  Does this mean that those of us who have owned shares prior to CBIS returning to private company status automatically have that status, or do we have to follow a very specific process in order for that to take place.  I have heard a number of thoughts on this, some of them conflicting, and really do not have a good sense of what the requirement is to be.

Anthony Is the Dutch auction going to happen or will you try to raise that 25 million dollar target another way this round. Basically what's going on with... Show more 4 years ago

American States University

Recent GBXI News:

June 22, 2023, GBX International Group, Inc., (OTC: GBXI)
Breaking Cancer Barriers; Investments in Low-Cost, Harvard Award-Winning, Effective Cancer Killing Drugs Now; GBXI Proceeds to Raise $1 Million to Fast-Track its' Success, Cancer Drug Valuations, Access for Patients, Full Company Audit, and Accelerate the Trading of the CSi-Spinout Shares

May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets

April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans

The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.

Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.

We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.

Click here to review the Report:

Case No. 2:17-CV-02271-KJM-JDP

Inspire, Dream, Change

YOUR DIGITAL ERA Personal & Business Access Learning HUB

Observational Studies

Groups

cancer survivors
- 4
- 2308
- 0
- 0
COVID-19 CoronaVirus
- 16
- 2780
- 2
- 0
Observational Studies
- 33
- 3042
- 3
- 0
Cannabis Science Pharmacies
- 39
- 6042
- 3
- 0
Investor Relations
- 614
- 16810
- 51
- 0

View all groups

Notifications

Photos

Activity Stream

I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever... Show more

Jon Morse, Richard A Nenzel and 2 others

Raymond C. Dabney Raymond C. Dabney Great questions as usual Francis, some a bit over the line comments and questions, but I get it.

"We Own everything we speak about Owning,... Show more 7 days ago

•••

Raymond C. Dabney Great questions as usual Francis, some a bit over the line comments and questions, but I get it.

"We Own everything we speak about Owning, that should go without saying, for example."

As you know we will be putting out public announcements as we proceed with new developments and our "inside info" becomes public.

"Cannabis Science Conferences" that action costs money as well to proceed, they have been using our name for years now and we've sent them plenty of warning letters.

EVERYTHING COSTS MONEY to move forward in this pubic company world.

"We are still waiting on the exchange to review more data we sent them, I spoke to them last on this last Friday."

Great questions however, our "Success Speed" moving forward is based on "raising capital to apply to operations strength and resources" just like any other Company.

You can be sure we are moving ast GODSPEED for a looong minute now.

All our Shareholders have be supporting the Company through Investments just like any other Company.

Our VIP Investors have REALLY Stepped up to keep us moving forward in the process, especially with this last CSi-VIP Cancer Killing Drug Legacy Ownership Opportunity.

*** Now, that I am "Not so Sick" and back in the Saddle we will be proceeding forward with the individual CSi-VIP Investor reports for the Legacy Drug Ownership Program.

I hope you invested as well. You know, it all Supports our Movement going forward and you receive the Benefits on Top of any Shares you did purchase as well.

Our VIP Investors can look forward to their personal reports and communications resumption beginning this weekend.

All the Best,
Talk soon
Raymond - IGWT

4 weeks ago
Like
5

Francis Cormier
Francis Cormier

Raymond, thank you so much for your response. I do understand that this whole process being undertaker costs a huge amount of $$$. At every turn of a corner that you take someone has their hand out. So I recognize the need for fundraising; BIG TIME. But, since Cannabis Science is NOT a Charity; all donations are not a tax deduction. Therefore you must solicit for the purchase of the Rule 144 Restricted shares. As is known, you do have a loyal following. However, you can't keep going to the same well.

4 weeks ago
Like
4
•••

Francis Cormier
Francis Cormier Also, In GOD We Trust, Everybody else pays cash,

4 weeks ago
Like
3

Raymond C. Dabney Raymond C. Dabney Everything has it's Priority. Not being sick anymore was Priority Number 1.

Now that I'm past that NASTY Sickness phase we can... Show more 7 days ago

•••

Raymond C. Dabney Everything has it's Priority. Not being sick anymore was Priority Number 1.

Now that I'm past that NASTY Sickness phase we can resume the FIREWORKS Prep.

Absolutely! This list is extensive for each Company and yes, of course, we are well aware of what needs to happen, don't forget that we provided them with all the info. Step by Step, Priority by Priority.

Cheers! and IGWT

All the reports will Fire Up again, once we get past this trading nightmare!

We have some Great unseen progress, so, it can't be tooo much longer now. We will light up the Fireworks!

2 months ago
Like
5
•••

Francis Cormier
Francis Cormier Thank you Raymond for your response. Glad to hear that you are on the mend. Best Regards, Francis - looking forward to future updates.

2 months ago
Like
7

Raymond C. Dabney
Raymond C. Dabney You're welcome and Thank you Francis! It's been a Battle, that's for sure! Playing catch up with everyone responding to the Legacy Drug Ownership program, I will get to everyone, Thanks for all your Patience! One Step at a Time. We'll be Professionals at that Two-Step when we are done.

Talk soon
Raymond - IGWT

2 months ago
Like
5

Raymond C. Dabney
Raymond C. Dabney Thanks for reading our updates Guys! That is correct we are ALL waiting patiently for the same stock exchange approval process.

Not sure how many updates we have written on this thus far, but we will keep going until it's done!

Thanks again
Talk soon Guys.
Raymond - IGWT

1 month ago
Like
4

Hi Raymond,

Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:

On November 8, 2023; Capizate, Inc. (a 3rd party entity) reported a "Situation Analysis of GBXi" that it performed at GBXI's request; based upon 25 documents provided by GBXI; mostly pertaining to Cannabis Science, Inc. This report included listing: (a) Strengths, (b) Areas for Improvement, (c) CBIS Cancer Drug Valuation(s) [1 specifically], (d) as well as several additional items that supported it giving GBXI a Capitize Score = 623 out of a possible 1000. Getting the potential CBIS Drug Valuation(s) for just 1 drug @ 25Mil-29Mil is/was impressive; however the "Areas for Improvement" are significant:

Areas for improvement
---------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.

Can you please let us know about the progress that has been made toward resolving these issues?? Even if you could reveal an estimated % complete for each line item that would be nice to see.

The report from November 8, 2023 says:  "Your current phase in our process is phase three (Situation Analysis), four (Due Diligence Score), and five (Business Finance Documents – Specifically the analysis) the potential valuation" - out of a 7 phase process; (6) Capital Markets and (7) Post Capitalization. Even if you choose not to continue to use Capitize, Inc. any longer; these "Areas of Improvement" listed MUST BE addressed in order to bring CBIS back Trading again.

Thank you in advance of your response and Best Regards,

...Francis G. Cormier III

Hi Raymond,

Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:

On November 8, 2023; Capizate, Inc. (a 3rd party entity)... Show more

Raymond C. Dabney, KELLY PINGSTERHAUS and 4 others

Show previous comments (1)

Francis Cormier Thank you Raymond for your response. Glad to hear that you are on the mend. Best Regards, Francis - looking forward to future updates. 2 months ago

•••

Raymond C. Dabney You're welcome and Thank you Francis! It's been a Battle, that's for sure! Playing catch up with everyone responding to the Legacy Drug Ownership... Show more 2 months ago

•••

Raymond C. Dabney Thanks for reading our updates Guys! That is correct we are ALL waiting patiently for the same stock exchange approval process.

Not sure how many... Show more 2 months ago

•••

Alvin Kline Who would be nice to see some trading going on won't be long I'm going to be in granite City I hope it don't take that long 2 weeks ago

•••

Alvin Kline Well for waiting for the government to get anything done we're in big trouble because they don't even know who the hell the president is yet 1 week ago

•••

Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"

HARVARD Award Winning
CANCER Killing Success

1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:

*** Please click image below.

2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:

*** Please click image below.

*** PLUS

(3) other Cannabis Science
REAL WORLD Successes:

Stage 4 Breast Cancer

Skin Cancer

Karposis Sarcoma

Cannabis Science CEO, Presents …

The FINAL “CBIS GIFT Shares” Issuances!

DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!

ALL GIFT Shares 1, 2, & 3 being ISSUED !!!

LAST Steps:

Please confirm Yours NOW !!!

1. CONFIRM Correct Total Share Amount(s)

2. CONFIRM Correct Name(s) on CERTIFICATE

3. CONFIRM Correct Mailing Address

*** giftshares@icannabinoid.com

ASU/CSi-EDP-ECO-System
At it's FINEST !!!

WHICH ONE ARE YOU ??

Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???

We can make this HAPPEN way FASTER Working as a TEAM !!!

WHAT Matters is how much you CARE about KILLING CANCERS ...

This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.

2023 Audit considerations NASDAQ.

Cannabis Science Inc.
Share Structure 2023

Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.

Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296

Class A Common Stock
Authorized:
100,000,000
Issued:
0

Class B Common Stock
Authorized:
1,500,000,000
Issued:
0

Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000

Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.

You already know our Extensive LIST of GROUNDBREAKING Products.

1-Million STRONG TV Coverage, HARVARD Award Success.

TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE

*** APPLY for FREE in CONFIDENCE and Success.

Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.

EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!